



# Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST

[CLICK HERE TO REGISTER](#)

VANCOUVER, BC, March 18, 2024 /CNW/ - **Asep Medical Holdings Inc. ("Asep Inc." or the "Company")** (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that it is holding an online webinar on **March 22, 2024, at 4:00 pm EST** to provide significant updates on the company's latest milestones.

Investors, potential investors, analysts, and members of the medical community are invited to register for the webinar to review Asep Inc.'s groundbreaking diagnostic and therapeutic technologies and learn first-hand about the status of the Company's plans to list on the Nasdaq Exchange. Members of Asep Inc.'s executive team will present the company's latest corporate presentation as well as update attendees on the status of our global partnerships and joint ventures.

## ABOUT ASEP MEDICAL HOLDINGS INC.

**Asep Medical Holdings Inc.** ([asepmedical.com](http://asepmedical.com)) is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine. The Company is a consolidation of three existing private companies, all with technology in advanced development — Sepset Biosciences Inc. (proprietary diagnostic tools to enable the early and timely identification of sepsis), ABT Innovations Inc. (broad-spectrum therapeutic agents to address multi-drug resistant biofilm infections), and SafeCoat Medical Inc. (an antimicrobial peptide, anti-fouling medical device coating technology).

**Sepset Biosciences Inc.** ([sepset.ca](http://sepset.ca)) is developing a diagnostic technology that involves a patient gene expression signature that predicts the development of severe sepsis, one of the significant diseases leading to antibiotic failure, since antibiotics are the primary treatment for sepsis. Sepsis was responsible for nearly 20% of all deaths on the planet in 2017 and essentially all deaths due to COVID-19 and other pandemics. The Sepset<sup>ER</sup> test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour after taking a blood sample in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling the diagnosis of severe sepsis within 60 minutes of initiating the test. Bacterial culture, the gold standard, provides a diagnosis after ~15 hours but can be as long as three days. Asep Inc. believes its test will enable physicians to make critical early decisions regarding appropriate therapies and thus reduce overall morbidity and mortality due to sepsis.

**ABT Innovations Inc.'s** ([abtinnovations.ca](http://abtinnovations.ca)) peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear-nose and throat, sinusitis, orthopaedic, etc.), anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. The company is in the pre-clinical development phase with promising data.

**SafeCoat Medical Inc.'s** ([safecoatmedical.com](http://safecoatmedical.com)) technology incorporates self-assembling biocompatible polymers that can be combined with conjugated antimicrobial peptides and applied to virtually any surface as stable antimicrobial and/or anti-fouling coatings. Of particular interest is the application of this versatile antimicrobial coating to various medical devices and implants that often become contaminated with biofilm infections. SafeCoat is optimizing methods to manufacture and apply these anti-bacterial coatings to a host of surfaces and can tailor the composition of the coating and associated peptide sequences for any desired application.

## FORWARD-LOOKING STATEMENTS —

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include but are not limited to the successful clinical testing of our Sepsis diagnostic test and its intended filing for regulatory approval; the Company not receiving regulatory approval as planned or at all; the undertaking of pre-clinical studies on our lead therapeutic, with the expectation that this will lead to fast-track clinical trials; the timeframe for diagnosis of sepsis with the company's products; the potential opportunities for the generation of revenue; the therapeutic benefits of the company's products; and other statements regarding the company's proposed business plans. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks including the risk that the company's products may not perform as expected; that the company may not receive the requisite regulatory approvals or results of testing; the Company's testing of the products may not be successful and approvals may not be obtained in the estimated timelines or at all; the company may not be able to generate revenue from its products as expected or at all; the market for the company's products may not be as described in this news release; and various other risk factors identified in the Asep Medical Inc.'s prospectus dated November 9, 2021, and in the company's management discussion and analysis, available for review under the Company's profile at [www.sedar.com](http://www.sedar.com) and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

View original content to download multimedia:

<https://www.prnewswire.com/news-releases/asep-medical-holdings-inc-to-hold-significant-investor-information-webinar-this-friday-march-22-2024-at-4-pm-est-302>

SOURCE ASEP Medical Holdings Inc.

View original content to download multimedia: <http://www.newswire.ca/en/releases/archive/March2024/18/c3502.html>

%SEDAR: 00053132E

**For further information:** Chris Dallin, Marketing Director, Asep Medical Holdings Inc., E. [chris@asepmedical.com](mailto:chris@asepmedical.com), T. +1 (604) 362-3654

CO: ASEP Medical Holdings Inc.

CNW 22:52e 18-MAR-24